Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Palvella Therapeutics, Inc (PVLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: PVLA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 33.87% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 219.38M USD | Price to earnings Ratio 9.92 | 1Y Target Price 37.33 |
Price to earnings Ratio 9.92 | 1Y Target Price 37.33 | ||
Volume (30-day avg) 75073 | Beta - | 52 Weeks Range 6.20 - 29.27 | Updated Date 03/15/2025 |
52 Weeks Range 6.20 - 29.27 | Updated Date 03/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 9.92 | Forward PE - | Enterprise Value 213128551 | Price to Sales(TTM) - |
Enterprise Value 213128551 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 11221300 | Shares Floating 3351754 |
Shares Outstanding 11221300 | Shares Floating 3351754 | ||
Percent Insiders 17.5 | Percent Institutions 36.51 |
Analyst Ratings
Rating 4.5 | Target Price - | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Palvella Therapeutics, Inc
Company Overview
History and Background
Palvella Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare, genetically defined skin diseases with no approved treatments. Founded in 2014, it has primarily focused on developing treatments for pachyonychia congenita (PC).
Core Business Areas
- Pharmaceutical Development: Focused on developing and commercializing novel therapies for rare dermatologic conditions with high unmet need, primarily pachyonychia congenita (PC).
- Research and Development: Conducting preclinical and clinical research to identify and develop potential drug candidates. Currently focused on their main therapy, PTX-022.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company has a typical organizational structure for a clinical-stage biopharmaceutical company, with departments focused on research, development, clinical operations, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- PTX-022 (ecalicabate): PTX-022 is a topical formulation of ecalicabate being developed for the treatment of pachyonychia congenita (PC). There are no currently approved treatments for PC. Market share is therefore undefined at present; potential competitors include companies developing alternative therapies or managing symptoms. Almirall and Timber Pharmaceuticals (TMBR) might develop competing treatments.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing growth, driven by scientific advancements and demand for novel therapies. The rare disease segment is particularly attractive due to orphan drug designations, which provide market exclusivity.
Positioning
Palvella Therapeutics, Inc. is positioned as a leader in developing therapies for PC. Its competitive advantage lies in its focus on this specific rare disease and the potential for PTX-022 to be the first approved treatment.
Total Addressable Market (TAM)
The estimated TAM for PC treatment is approximately $500 million annually. Palvella is positioning itself to capture a significant portion of this market with PTX-022, assuming successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Focus on a rare disease with high unmet need
- Potential first-in-class therapy
- Experienced management team
- Orphan drug designation for PTX-022
Weaknesses
- Single product focus increases risk
- Limited financial resources compared to larger pharmaceutical companies
- Development and regulatory risks associated with clinical trials
- Reliance on successful commercialization of PTX-022
Opportunities
- Potential for expansion into other rare dermatologic diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results driving investor interest
- Accelerated regulatory pathways for rare disease therapies
Threats
- Failure to obtain regulatory approval for PTX-022
- Competition from other companies developing therapies for PC
- Changes in regulatory environment affecting orphan drug designations
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- Almirall (ALM)
- Timber Pharmaceuticals (TMBR)
Competitive Landscape
As there are no currently approved treatments for PC, the competitive landscape is focused on companies developing potential therapies. Palvella's PTX-022 is currently a leading candidate. Any current market share is only for symptom relief.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is currently tied to clinical trial progress and potential regulatory approval of PTX-022.
Future Projections: Future growth is dependent on successful commercialization of PTX-022 and expansion into other indications.
Recent Initiatives: Focusing on advancing PTX-022 through clinical trials and preparing for potential commercialization.
Summary
Palvella Therapeutics is a focused company developing a potential first-in-class treatment for a rare disease. Its success hinges on the approval and commercialization of PTX-022. The company faces risks associated with clinical trials, regulatory approval, and competition from alternative therapies, but its focus on an unmet need offers significant opportunity.
Similar Companies
- ALM
- TMBR
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- SEC Filings of Competitors
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. This analysis is based on publicly available information and may not be complete or accurate. The stock symbol may reflect public competitors not the private company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Palvella Therapeutics, Inc
Exchange NASDAQ | Headquaters Wayne, PA, United States | ||
IPO Launch date 2024-12-16 | Founder, President, CEO & Director Mr. Wesley H. Kaupinen | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://palvellatx.com |
Full time employees - | Website https://palvellatx.com | ||
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.